*Read Disclaimer Sponsored Content
{{current_date_full}} | Unsubscribe
Hello!
We wanted to give you a quick intraday update on our new alert, NanoViricides, Inc. (NYSE American: NNVC).
NNVC opened today at 1.24 and has already rallied to a high of 1.31 (+5%) - moving in the right direction following this morning's alert.
NNVC has a history of delivering double-digit gains following our past alerts, with previous breakouts reaching +35%, +53%, +44%, and +25%.
Now, after building momentum over the past few weeks, it looks to be setting up for another potential breakout.
The key level to watch right now: the 200-day moving average of 1.30.
NNVC is pressing right up against it. A breakout and close above this level could set in motion a much greater opportunity - with last week's high of 1.49 as the first upside target, +20% above today's open.
The news driving this story could not be more timely.
Last week, the company announced:
“Deadly Measles Cases Accentuate the Need for a Treatment - NV-387 is Here to Help Patients and Control Spread, Says NanoViricides”
Here is the scale of the current outbreak:
“Bangladesh recently reported 18,219 suspected measles cases, including 2,897 confirmed cases, and 164 suspected case deaths, with transmission in 58 of 64 districts, in the single month of March 15 to April 14, 2026[1]. Over 80% of the cases are in children under the age of 5 years, and most of the deaths are in unvaccinated cases. The nation has rolled out a vaccination campaign which is expected to reach 1.2 million children in 18 of the 64 districts in the first phase.”
NNVC's lead drug candidate NV-387 is, in the company's words, “currently the only medical countermeasure that can help these patients and save lives."
Importantly, “NV-387 has completed a Phase I clinical trial with no reported adverse events, indicating excellent safety and tolerability in humans”.
A treatment such as NV-387 would help curtail the transmission chain as well, which would help stall the epidemic sooner.
“In contrast to the immediate effect of drug treatment, a vaccinated individual becomes protected only after 2-3 weeks post vaccination; so they continue to remain at risk while immersed in the epidemic.”
This is a meaningful clinical and commercial differentiator in an active outbreak.
Furthermore, as the company notes: “NV-387, we believe, is the only drug candidate that has been shown to be effective and safe in specially humanized animal model studies of lethal Measles virus infection”.
Measles is considered a rare orphan disease in the USA. It is also a rare pediatric disease.
As such, NV-387 for the treatment of Measles would qualify for an Orphan Drug Designation (ODD) together with a Rare Pediatric Disease Drug (RPDD) designation.
NanoViricides has applied for NV-387 as a treatment for measles for ODD as well as RPDD to the US FDA.
Beyond that, earlier in April, the company announced:
“Phase II Clinical Trial of Monkeypox Treatment by NV-387 to Commence Soon, Announces NanoViricides”
“The Company previously reported that it has received approval to start said Phase II Clinical Trial of NV-387 for the Treatment of MPox by the Regulatory Agency ACOREP of the Democratic Republic of Congo (DRC).”
“The Phase II clinical trial will evaluate safety and effectiveness of NV-387 for the treatment of patients with MPox disease caused by hMPXV infection.”
Here are some of the company’s comments from this press release:
"This is an important milestone in regulatory development of NV-387," said Anil R. Diwan, PhD, President and Executive Chairman of the Company.
We are watching for NNVC to hold above today's open of 1.24, close above the 200-day moving average of 1.30, and push toward last week's high of 1.49 as confirmation of the next leg higher.
We are continuing to monitor NNVC for a sustainable breakout higher.
Happy Trading!
SmallCapStocks Team
Note: We encourage all traders and investors to develop personal trading rules that you can follow and that work for you. Always protect your downside and note that we alert extremely volatile short-term opportunities. Before investing in securities, you should always consult with your financial, tax and legal advisor and never invest money you cannot afford to lose.
DISCLAIMER:
You should read and understand this disclaimer in its entirety before joining the website or email/blog list of SmallCapStocks.com (the “Publisher”). The information (collectively the “Advertisement”) disseminated by email, text or other method by the Publisher including this publication is a paid commercial advertisement and should not be relied upon for making an investment decision or any other purpose. The Publisher is engaged in the business of marketing and advertising the securities of publicly traded companies in exchange for compensation. The track record, gains, upside, and/or losses mentioned in the Advertisement, if any, should not be considered as true or accurate or be the basis for an investment. The Publisher does not verify the accuracy or completeness of any information included in the Advertisement. While the Publisher does not charge for the SMS service, standard carrier message and data rates may apply. To unsubscribe from receiving promotional text messages to your phone sent via an autodialer, using your phone reply to the sender’s phone number with the word STOP or HELP for help.
The Advertisement is not a solicitation or recommendation to buy securities of the advertised company. An offer to buy or sell securities can be made only by a disclosure document that complies with applicable securities laws and only in the states or other jurisdictions in which the security is eligible for sale. The Advertisement is not a disclosure document. The Advertisement is only a favorable snapshot of unverified information about the advertised company. An investor considering purchasing the securities, should always do so only with the assistance of his legal, tax and investment advisors. Investors should review with his or her investment advisor, tax advisor or attorney, if and to the extent available, any information concerning a potential investment at the web sites of the U.S. Securities and Exchange Commission (the "SEC") at www.sec.gov; the Financial Industry Regulatory Authority (the "FINRA") at www.FINRA.org, and relevant State Securities Administrator website and the OTC Markets website at www.otcmarkets.com. The Publisher cautions investors to read the SEC advisory to investors concerning Internet Stock Fraud at www.sec.gov/consumer/cyberfr.htm, as well as related information published by the FINRA on how to invest carefully. Investors are responsible for verifying all information in the Advertisement. As an advertiser, we do not verify any information we publish. The Advertisement should not be considered true or complete.
The Publisher does not offer investment advice or analysis, and the Publisher further urges you to consult your own independent tax, business, financial and investment advisors concerning any investment you make in securities particularly those quoted on the OTC Markets. Investing in securities is highly speculative and carries an extremely high degree of risk. You could lose your entire investment if you invest in any company mentioned in the Advertisement. You acknowledge that we are not an investment advisory service, a broker-dealer or an investment adviser and we are not qualified to act as such. You acknowledge that you will consult with your own independent, tax, financial and/or legal advisers regarding any decisions as to any company mentioned here. We have not determined if the Advertisement is accurate, correct or truthful. The Advertisement is compiled from publicly available information, which include, but are not limited to, no cost online research, magazines, newspapers, reports filed with the SEC or information furnished by way of press releases. Because all information relied upon by us in preparing an advertisement about an issuer comes from a public source, it is not reliable, and you should not assume it is accurate or complete.
Owners and operators of the Publisher have been compensated eight thousand dollars by bank wire transfer on 4/28/26 for the distribution of this advertisement about NNVC dated 5/1/26. Previously, owners and operators of the Publisher have been compensated nine thousand dollars by bank wire transfer on 3/13/26 for the distribution of a prior advertisement about NNVC. Previously, owners and operators of the Publisher have been compensated nine thousand dollars by bank wire transfer on 2/17/26 for the distribution of a prior advertisement about NNVC. Previously, owners and operators of the Publisher have been compensated eight thousand dollars by bank wire transfer on 1/12/26 for the distribution of a prior advertisement about NNVC. Previously, owners and operators of the Publisher have been compensated eight thousand dollars by bank wire transfer on 12/30/25 for the distribution of a prior advertisement about NNVC. Previously, owners and operators of the Publisher have been compensated eight thousand dollars by bank wire transfer on 10/29/25 for the distribution of a prior advertisement about NNVC. Previously, owners and operators of the Publisher have been compensated eight thousand dollars by bank wire transfer on 10/16/25 for the distribution of a prior advertisement about NNVC. Previously, owners and operators of the Publisher have been compensated a total of eight thousand dollars by bank wire transfer on 6/20/25 for the distribution of a prior advertisement about NNVC. Previously, owners and operators of the Publisher have been compensated a total of eight thousand dollars by bank wire transfer on 6/20/25 for the distribution of a prior advertisement about NNVC. Prior to the past year, at the time of publication, we disclosed our compensation for the distribution of advertisements about NNVC. The Publisher and its owners and operators hold no stocks or bonds in companies discussed in the Advertisement. Owners and operators of the Publisher own several newsletters, therefore you may receive multiple publications and emails featuring companies at different or the same time.
You are receiving this report/release because you subscribed to receive it at our website or through a third-party site. All our newsletters include an "unsubscribe" link, and you can remove yourself at any time from our newsletters by clicking on that "unsubscribe" link. You can also contact us at [email protected] to change your information at any time. By your subscription to our profiles, the viewing of this profile and/or use of our website, you have agreed and acknowledged the terms of our full disclaimer and privacy policy which can be viewed at the following link:
www.SmallCapStocks.com/Disclaimer and www.SmallCapStocks.com/Privacy-Policy
By accepting the Advertisement, you agree and acknowledge that any hyperlinks to the website of (1) a client company, (2) the party issuing or preparing the information for the company, or (3) other information contained in the Advertisement is provided only for your reference and convenience. The advertiser is not responsible for the accuracy or reliability of these external sites, nor is it responsible for the content, opinions, products or other materials on external sites or information sources. If you use, act upon or make decisions in reliance on information contained in any disseminated report/release or any hyperlink, you do so at your own risk and agree to hold us, our officers, directors, shareholders, affiliates and agents harmless. You acknowledge that you are not relying on the Publisher, and we are not liable for, any actions taken by you based on any information contained in any disseminated email or hyperlink.